News and Updates

The FDA has approved Phase I clinical trials for ASC35, a monthly GLP-1R/GIPR dual agonist aimed at revolutionizing obesity treatment via long-acting dosing.

New study shows general-purpose AI is beating FDA-cleared clinical tools. Explore the growing validation gap and what it means for the future of healthcare.

The FDA is reviewing Regeneron's cemdisiran for generalized myasthenia gravis. Learn how this RNAi therapy targets the complement system for gMG treatment.

A Phase 2 trial reveals that infigratinib offers promising results for patients with FGFR2-amplified advanced gastric or GEJ adenocarcinoma.

Major Indian pharma stocks rally as the US FDA seeks to address critical cancer drug shortages by engaging top manufacturers for increased supply.

VahatiCor has enrolled its first U.S. patient in a clinical trial for the A-FLUX Reducer System, a novel device targeting Coronary Microvascular Dysfunction.

The FDA has launched a new pilot program to accelerate drug testing and innovation in response to the growing global competition in the biotech sector.

Pfizer’s experimental lung cancer drug missed its primary endpoint in a Phase 3 trial. Discover what this setback means for oncology and patient treatment.

Health officials are implementing strict clinical trial reforms to protect research integrity and national security from growing foreign threats.

The FDA is launching new strategies to accelerate drug development, focusing on improved trial designs and real-world evidence to fast-track innovation.